| Bioactivity | Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization[1]. | ||||||||||||
| Invitro | Tasisulam (200 nM-200 μM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC50s of 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively[1]. Tasisulam (25, 50 μM; 72 hours) induces a concentration-dependent increase in 4N DNA and G2-M accumulation[1]. Tasisulam (200 nM-200 μM; 48 hours) induces apoptosis in a broad range of in vitro cancer cell models[1]. Tasisulam also blocks VEGF, epidermal growth factor, and fibroblast growth factor-induced endothelial cell cord formation[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | Tasisulam | ||||||||||||
| CAS | 519055-62-0 | ||||||||||||
| Formula | C11H6BrCl2NO3S2 | ||||||||||||
| Molar Mass | 415.11 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Tasisulam
CAS: 519055-62-0 F: C11H6BrCl2NO3S2 W: 415.11
Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and c
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.